Reformulary 2019 Year in Review

From plan sustainability, including high savings and a low inflation rate, to new and pipeline drug reviews (185 of them!), to extensive data analysis and a suite of medical cannabis tools, we continue to make a remarkable difference. “Making Sense of Medicine” for Canadians and organizations is what we do best.

We have several exciting things in the works for 2020, so keep in touch with us via Twitter, LinkedIn or by visiting the news section of our website regularly.

Reformulary 2019 Year-In-Review